arrow_back Back to App

Faster Generic Drugs: Ending Safety Patent Blocks on Competition.

This bill aims to speed up access to cheaper generic drugs by preventing companies from using patents related to drug safety procedures (REMS) to intentionally delay the market entry of generic versions. This change ensures that citizens can access lower-cost medications sooner, fostering greater competition in the pharmaceutical market.
Key points
Limits the ability of drug companies to block generic drug entry by patenting drug safety protocols (REMS).
If a patent dispute arises over REMS, the original drug manufacturer can only seek monetary damages, not an order to stop the sale of the cheaper generic alternative.
The goal is to increase competition for prescription drugs, which is expected to result in lower costs for patients.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_574
Sponsor: Sen. Hassan, Margaret Wood [D-NH]
Process start date: 2023-03-01
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Increasing Prescription Drug Competition Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_574.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2023-03-01.

What are the main provisions?

Key points include:

  • Limits the ability of drug companies to block generic drug entry by patenting drug safety protocols (REMS).
  • If a patent dispute arises over REMS, the original drug manufacturer can only seek monetary damages, not an order to stop the sale of the cheaper generic alternative.
  • The goal is to increase competition for prescription drugs, which is expected to result in lower costs for patients.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Hassan, Margaret Wood [D-NH].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

CATEGORIES

Health Economy